Monte Rosa Partners With Novartis To Advance Breakthrough VAV1 Molecular Glue Degraders

Monte Rosa Therapeutics, Inc., a biotechnology company focused on developing new medicines based on molecular glue degraders (MGDs), has completed its global exclusive license agreement with Novartis. This deal will support the development and commercialization of VAV1-targeted MGDs, including MRT-6160. Under the agreement, Novartis will have exclusive global rights to develop, manufacture, and sell MRT-6160 and other VAV1-targeted MGDs. They will handle all clinical development and commercialization, starting with Phase 2 trials. Monte Rosa will continue overseeing the ongoing Phase 1 study of MRT-6160. 

Novartis will pay Monte Rosa $150 million upfront and could pay up to $2.1 billion in milestone payments tied to development, regulatory approvals, and sales. Monte Rosa will also receive royalties on sales outside the U.S. and will share costs and profits for any Phase 3 trials and U.S. commercialization of MRT-6160. MRT-6160 is an investigational drug that targets and degrades VAV1, a key protein involved in immune signaling. It is highly selective, potent, and can be taken orally. Preclinical studies have shown that MRT-6160 effectively reduces VAV1 levels, leading to a decrease in cytokines associated with immune-related conditions, without affecting other proteins. It has shown promising results in preclinical models for several immune-mediated diseases.